Eosinophilic pustular folliculitis effectively treated with recombinant interferon-γ: Suppression of mRNA expression of interleukin 5 in peripheral blood mononuclear cells

British Journal of Dermatology

Volumn 134, Issue 4, 1996, Pages 766-772

  Fushimi, M ^a   Tokura, Y ^a   Sachi, Y ^a   Hashizume, H ^a   Sudo, H ^a   Wakita, H ^a   Furukawa, F ^a   Takigawa, M ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOGAMMA; CORTICOSTEROID; DAPSONE; INTERLEUKIN 5; MESSENGER RNA; MINOCYCLINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RECOMBINANT GAMMA INTERFERON; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; CLINICAL TRIAL; FOLLICULITIS; HELPER CELL; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PUSTULE;

EID: 0030001997     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1996.tb06988.x     Document Type: Article

References (30)

1. Ofuji S, Ogino A, Horio T et al. Eosinophilic pustular folliculitis. Acta Derm Venereol (Stockh) 1970; 50: 195-203.
2. Teraki Y, Konohana I, Shiohara T et al. Eosinophilic pustular folliculitis (Ofuji's disease). Immunohistochemical analysis. Arch Dermatol 1993; 129: 1015-19.
3. Weller PF, Rand TH, Goelz SE et al. Human eosinophils adherence to vascular endothelium mediated by binding to vascular cell adhesion molecule 1 and endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci USA 1991; 88: 7430-3.
4. Wardlaw AJ, Moqbel R, Cromvell O, Kay AB. Platelet-activating factor: a potent chemotactic and chemokinetic factor for human eosinophils. J Clin Invest 1986; 78: 1701-6.
5. Takematsu H, Tagami H. Eosinophilic pustular folliculitis: studies on possible chemotactic factors involved in the formation of pustules. Br J Dermatol 1986; 114: 209-15.
6. Sanderson CJ. Interleukin 5, eosinophils, and disease. Blood 1992; 79: 3101-9.
7. Campbell HD, Tucker WQJ, Hort Y et al. Molecular cloning, nucleotide sequence, and expression of the gene coding human eosinophil differentiation factor (interleukin 5). Proc Natl Acad Sci USA 1987; 84: 6629-33.
8. Rothenberg ME, Peterson J, Stevens RL et al. IL-5 dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity and sustained antibody-dependent cytotoxicity. J Immunol 1989; 143: 2311-16.
9. Lopez AF, Begley CG, Williamson DJ et al. Murine eosinophil differentiation factor: an eosinophil-specific colony-stimulating factor with activity for human cells. J Exp Med 1986; 163: 1085-99.
10. Enokihara H, Furusawa S, Nakakubo H et al. T cells from eosinophilic patients produce interleukin-5 with interleukin-2 stimulation. Blood 1989; 73: 1809-13.
11. Dent LA, Strath M, Mellor AL, Sanderson CJ. Eosinophilia in transgenic mice expressing interleukin 5. J Exp Med 1990; 172: 1425-31.
12. Enokihara H, Kijitani H, Nagashima S et al. Interleukin 5 activity in sera from patients with eosinophilia. Br J Haematol 1990; 75: 458-62.
13. Takamizawa M, Iwata T, Watanabe K et al. Elevated production of interleukin-4 and interleukin-5 by T cells in a child with idiopathic hypereosinophilic syndrome. J Allergy Clin Immunol 1994; 93: 1076-8.
14. Miyauchi T, Tanigaki H, Uehara M et al. Effect of indomethacin on eosinophilic pustular folliculitis. Acta Dermatol (Kyoto) 1985; 80: 9-13.
15. Tanigaki T, Kakeda R. Two cases of eosinophilic pustular folliculitis successfully treated with minocycline. Hifuka-no-Rinsho 1984; 26: 1129-33 (in Japanese).
16. Steffen C. Eosinophilic pustular folliculitis (Ofuji's disease) with response to dapsone therapy. Arch Dermatol 1985; 121: 921-3.
17. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
18. Ehlers S, Smith KA. Differentiation of T cell lymphokine gene expression: the in vitro acquisition of T cell memory. J Exp Med 1991; 173: 25-36.
19. Romagnani S. Human Th1 and Th2 subsets: doubt no more. Immunol Today 1991; 12: 256-7.
20. Bouguniewicz M, Jaffe HS, Izu A et al. Recombinant gamma interferon in treatment of patients with atopic dermatitis and elevated IgE levels. Am J Med 1990; 88: 365-70.
21. Hanifin JM, Schneider LC, Leung DYM et al. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 1993; 28: 189-97.
22. Geha RS. Regulation of IgE synthesis in humans. J Allergy Clin Immunol 1992; 90: 143-50.
23. Lamas AM, Mulroney CR, Schleimer RP. Studies on the adhesive interaction between purified human eosinophils and cultured vascular endothelial cells. J Immunol 1988; 140: 1500-5.
24. Nickoloff BJ. Role of gamma interferon in cutaneous trafficking of lymphocytes with emphasis on molecular and cellular adhesion events. Arch Dermatol 1988; 124: 1835-43.
25. Valerius T, Repp R, Kalden JR, Platzer E. Effects of IFN on human eosinophils in comparison with other cytokines. A novel class of eosinophil activators with delayed onset of action. J Immunol 1990; 145: 2950-8.
26. Czeck W, Krutman J, Budnik A et al. Induction of intercellular adhesion molecule 1 (ICAM-1) expression in normal human eosinophils by inflammatory cytokines. J Invest Dermatol 1993; 100: 417-23.
27. Moqbel R, Hamid Q, Ying S et al. Expression of mRNA and immunoreactivity for the granulocyte/macrophage colony-stimulating factor in activated human eosinophils. J Exp Med 1991; 174: 749-52.
28. Lee SW, Honh D, Kim HO et al. Clinical trials of interferon-gamma in treating warts. Ann Dermatol 1990; 2: 77-82.
29. Granstein RD, Rook A, Flotte TJ et al. A controlled trial of intralesional recombinant interferon-γ in the treatment of keloidal scarring. Arch Dermatol 1990; 126: 1295-302.
30. Hein R, Behr K, Hündgen M et al. Treatment of systemic sclerosis with γ-interferon. Br J Dermatol 1992; 126: 496-501.